ArticleCureus2026
Association of Prothrombotic and Oxidative Stress Biomarkers With the Risk of Microvascular Dysfunction in Patients With Type 2 Diabetes Mellitus.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Type 2 diabetes mellitus is a common metabolic disorder associated with progressive vascular complications. Microvascular dysfunction is an important cause of diabetic nephropathy, retinopathy, and neuropathy. Oxidative stress and prothrombotic activity are considered major contributors to vascular injury among diabetic patients. This study aimed to evaluate the association of prothrombotic and oxidative stress biomarkers with microvascular dysfunction risk in patients with type 2 diabetes mellitus. Methods This hospital-based observational cross-sectional study was conducted at Maryam Medicare Hospital, Vehari, Pakistan, from February 2025 to January 2026. A total of 200 patients with type 2 diabetes mellitus were included using consecutive sampling. Patients were divided into low-risk and high-risk microvascular dysfunction groups based on clinical and biochemical assessment. Prothrombotic biomarkers including fibrinogen, D-dimer, and plasminogen activator inhibitor-1 (PAI-1) were measured along with oxidative stress biomarkers including malondialdehyde (MDA), total antioxidant capacity (TAC), superoxide dismutase (SOD), glutathione (GSH), and catalase activity. Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 26 (Released 2018; IBM Corp., Armonk, New York, United States). Results Patients with high microvascular dysfunction risk showed significantly increased fibrinogen (421.5 ± 72.4 vs 312.8 ± 48.6 mg/dL), D-dimer (458.7 ± 101.5 vs 228.4 ± 62.1 ng/mL), PAI-1 (34.2 ± 8.7 vs 18.7 ± 5.4 ng/mL), and MDA levels (4.86 ± 0.92 vs 2.41 ± 0.58 nmol/mL) compared with the low-risk group (p < 0.001). Antioxidant biomarkers including TAC, SOD, GSH, and catalase were significantly reduced in high-risk patients (p < 0.001). MDA showed the highest predictive value for microvascular dysfunction risk with an area under the curve (AUC) of 0.871. Conclusion Elevated thrombotic and oxidative stress biomarkers were significantly associated with the presence of microvascular complications in patients with type 2 diabetes mellitus. These findings suggest that these biomarkers may reflect the burden of vascular injury and oxidative stress in patients with established diabetic microvascular complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.